Transmedics Group Stock Price, News & Analysis

On November 4, 2021, TransMedics Group announced positive topline results from its OCS DCD Heart Trial, the first randomized trial comparing outcomes of hearts from DCD donors using the OCS Heart System to those from DBD donors. The trial achieved a 95% patient survival rate at 6 months for the OCS DCD arm, outperforming the 89% for DBD controls. A total of 90 out of 101 DCD donor hearts were successfully transplanted, yielding an impressive 89% utilization rate. These results will be submitted to the FDA for further OCS DCD heart indication approval.

TransMedics Group (TMDX) will announce its third-quarter financial results on November 9, 2021, after market close. A conference call with management is scheduled for 4:30 p.m. ET. The company specializes in organ transplant technology, focusing on enhancing organ quality and viability for patients with end-stage organ failure. Investors can listen to the call by dialing specific numbers provided or accessing the webcast on TransMedics’ website.

TransMedics Group, Inc. (Nasdaq: TMDX) announced FDA premarket approval for its OCS Liver System on September 29, 2021, marking it as the first liver perfusion technology approved in the U.S. This system enhances the preservation and monitoring of liver allografts, facilitating the assessment of donor livers from both DBD and DCD sources. The approval is based on results from the OCS Liver PROTECT Trial and positions TransMedics to expand its commercial efforts for lung, heart, and liver transplantation, aiming to increase the availability of donor organs.

TransMedics Group, Inc. (TMDX) announced FDA premarket approval (PMA) for its OCS Heart System for donor hearts from patients with brain death. This approval enhances the preservation of hearts previously deemed unsuitable for transplantation, following the OCS Heart EXPAND Trial. The system allows real-time assessment of donor heart viability, potentially increasing the donor pool and meeting the growing demand for heart transplants in the U.S. TransMedics aims to commercialize the OCS Heart System and expand its clinical indications while continuing to seek regulatory approval for its OCS Liver System.

TransMedics Group, Inc. (Nasdaq: TMDX) announced on August 4, 2021, the grant of non-qualified stock options totaling 160,800 shares to five employees. This move, aimed at incentivizing new hires, was approved by the Board of Directors and follows Nasdaq Listing Rule 5635(c)(4). Notably, Chief Digital Officer Rakesh Godhani received options for 140,000 shares at an exercise price of $27.87, the stock's closing price on that date. The options vest over a four-year period and have a 10-year term.

TransMedics specializes in organ transplant technology.

TransMedics Group, Inc. (Nasdaq: TMDX) reported a strong second quarter for 2021, with a net revenue of $8.2 million, a remarkable 141% increase over the same period last year. This growth was driven by increased sales of its OCS Lung and Heart sets. Gross margin improved to 68%, up from 56% a year ago. However, net loss widened to $10.7 million compared to $8.5 million in Q2 2020, reflecting increased operating expenses of $15.5 million. The company's cash position remains strong at $112.2 million as of June 30, 2021.

TransMedics Group, Inc. (Nasdaq: TMDX) announced FDA 510(k) clearance for its OCS™ Lung Solution, enabling the cold storage of donor lungs for transplantation. This achievement highlights the company's focus on advancing organ transplant therapy. The OCS Lung Solution is a sterile, low potassium solution with a shelf life of 24 months. Additionally, the OCS Lung System is already approved in the U.S., while the OCS Heart and Liver Systems await FDA review. CEO Waleed Hassanein emphasized TransMedics' commitment to providing innovative organ preservation products.

TransMedics Group, Inc. (Nasdaq: TMDX) announced that its management team will engage in a virtual fireside chat during the Canaccord Genuity 41st Annual Growth Conference on August 11, 2021, at 4:30 p.m. ET. This discussion will be accessible via a live and archived webcast in the Investors section of the TransMedics website. Based in Andover, Massachusetts, TransMedics is pioneering portable organ perfusion technology to enhance organ transplantation outcomes, addressing critical needs in heart, lung, and liver failure treatment.

TransMedics Group, Inc. (TMDX), a leader in organ transplant technology, will release its second quarter financial results on August 5, 2021, after market close. The management team will host a conference call at 4:30 p.m. ET. Interested investors can join by dialing (833) 378-1026 or (236) 712-2500 for international calls. TransMedics focuses on improving organ quality and viability assessments, addressing the critical need for better organ transplants for patients with end-stage heart, lung, and liver failure.